Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cabaletta Bio, Inc.NASDAQ: CABA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $337K fell 30.5% year over year, behind the -16.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -30.5% toward the trailing-twelve-month pace of -16.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.65M USD
- Year-over-year change
- -3.8%
- 4-year CAGR
- +22.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.65M | -3.8% |
| FY2024 | 2024-12-31 | 1.71M | +20.0% |
| FY2023 | 2023-12-31 | 1.43M | +21.1% |
| FY2022 | 2022-12-31 | 1.18M | +60.7% |
| FY2021 | 2021-12-31 | 733K | — |
Depreciation & Amortization vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.9% is the 8th highest of 11, against a peer median of -1.3%.
- Over three fiscal years its annual growth of +11.8% compares with a peer median of -1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.25B USD | +83349.3% | +52.5% | — | |
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -11.2% | 33645.2% | |
| LTM Mar 2026 | $6.86M USD | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $4.17M USD | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| FY2025 | A$2.39M AUD | +5.6% | +5.0% | 47.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M USD | -1.7% | -30.8% | — |
| LTM Mar 2026 | $1.65M USD | -23.4% | +19.6% | — | |
| LTM Mar 2026 | $1.5M USD | -16.9% | +11.8% | — | |
| LTM Mar 2026 | $416K USD | +0.0% | +17.0% | — | |
| Peer median (excluding CABA) | — | -1.3% | -1.9% | 47.4% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.8M | 6.9M | 11.34M | 19.47M | 20.94M |
| Change in Working Capital | 5.58M | (4.3M) | 101K | 1.61M | (379K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 975K | (28K) | 1.68M | 1.01M | 1.55M |
| Other Working Capital | 4.61M | (4.27M) | (1.57M) | 600K | (1.93M) |
| Other Non-Cash Items | 62K | 2.82M | 1.26M | 4.86M | 14.57M |
| Operating Cash Flow | (34.11M) | (46.38M) | (53.55M) | (88.22M) | (131.08M) |
| Capital Expenditures | (1.17M) | (2.45M) | (687K) | (2.21M) | (1.23M) |
| Acquisitions (Net) | 0 | 24.76K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (49.76M) | (84.26M) | 0 | (99.04M) |
| Sales of Investments | 7.17M | 25M | 62.5M | 49.5M | 50M |
| Other Investing Activities | 0 | (24.76K) | 0 | 0 | 0 |
| Investing Cash Flow | 6M | (27.22M) | (22.45M) | 47.29M | (50.27M) |
| Debt Repayment | 0 | 0 | 0 | (897K) | (6.26M) |
| Common Stock Issued | 48.25M | 32.86M | 185.2M | 10.88M | 106.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 650K | 127K | 2.43M | 1.7M | 0 |
| Financing Cash Flow | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M |
| Effect of Forex Changes | 0 | 0 | 0 | (20K) | 19K |
| Net Change in Cash | 20.79M | (40.62M) | 111.63M | (29.28M) | (80.98M) |
| Free Cash Flow | (35.28M) | (48.83M) | (54.24M) | (90.43M) | (132.31M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.